RheumSpecialty appeals · Rheumatology (biologics & JAK)

Rheumatology denials: appealing biologic and JAK step-therapy denials

Rheumatology biologic denials almost always say the same thing: try the conventional DMARD first. The answer is usually already in the chart — the DMARD trail and a disease-activity score — it just has to be put where the reviewer looks.

Denials of biologics and JAK inhibitors in rheumatology — for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and related conditions — are predominantly step-therapy denials: the plan wants conventional DMARDs (often methotrexate) tried first, plus a documented disease-activity measure. The clinical case usually meets ACR treatment guidance; the denial fires on documentation, and a contraindication or intolerance to the required DMARD counts as a satisfied step.

Why these denials happen

Plans require a documented trial of conventional synthetic DMARDs before a biologic or JAK inhibitor, supported by a disease-activity score (such as DAS28 or CDAI) and the diagnosis. ACR guidance supports escalation to a biologic when conventional therapy fails or isn't tolerated. The denial is a documentation gap — the DMARD trail, the contraindication, or the activity score isn't mapped to the plan's criteria — not usually a dispute about whether the drug is appropriate.

The common denials

  • Step therapy: a conventional DMARD (e.g., methotrexate) trial wasn't documented as failed, intolerant, or contraindicated.
  • No documented disease-activity score establishing moderate-to-high activity.
  • Prior authorization criteria for the diagnosis or severity not met in the record.
  • Non-preferred biologic chosen without rationale over the plan's preferred agent.
  • Reauthorization denied — continued response not re-documented.

Is it worth appealing?

Often worth appealing

Usually worth appealing: the DMARD trail and a current disease-activity score, mapped to the plan's criteria and ACR guidance, carry most rheumatology biologic appeals. A contraindication or intolerance to the required conventional DMARD counts as a met step — make that explicit. The objective activity measure (DAS28/CDAI) is the lever rheumatology has that many specialties don't.

How to appeal

  1. 1

    Document the DMARD trail or contraindication

    Show the trial, failure, intolerance, or contraindication of the conventional DMARDs the plan requires — the contraindication itself satisfies the step.

  2. 2

    Attach a disease-activity score

    Include a current DAS28, CDAI, or comparable measure establishing moderate-to-high activity; it's the objective anchor of the appeal.

  3. 3

    Cite ACR guidance and the plan's criteria together

    Map the diagnosis, severity, and prior therapy to both the ACR treatment recommendations and the plan's specific prior-auth criteria.

Frequently asked

The plan denied my biologic for 'step therapy' — I can't take methotrexate.
An intolerance or contraindication to the required DMARD counts as having met the step. Document it explicitly (the reason methotrexate is contraindicated or wasn't tolerated) and appeal on that basis.
What's the single most useful document?
A current disease-activity score (DAS28/CDAI) paired with the DMARD history — the objective measure plus the trail is what most plan criteria and ACR guidance turn on.

Related guides

Gastroenterology IBD denialsCO-50 · medical necessityCO-197 · auth absent

Sources

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →